多西他赛与吉西他滨分别联合顺铂治疗晚期 非小细胞肺癌的临床观察
Clinical Observation of Docetaxel or Gemcitabine Combine with Cisplatin in Treatment of Patients with Advanced Non-small Cell Lung Cancer
-
摘要: 目的 评价多西他赛和吉西他滨分别联合顺铂治疗晚期非小细胞肺癌的疗效和不良反应。方法 76例晚期非小细胞肺癌患者随机分为两组：DP组：多西他赛75 mg/m2，d1，DDP 60mg/m2，d1；GP组：吉西他滨1000 mg/m2，d1，d8，顺铂用量同前。以上方案均21天为1周期，2~4周期评估疗效。结果 DP组总有效率43.5%，初治有效率53.8%，复治有效率23.0%。GP组总有效率45.9%，初治有效率56.0%，复治有效率25.0%。两组初治与复治相比，差异均有统计学意义（P<0.05）。两组的主要不良反应为骨髓抑制和消化道反应。结论 多西他赛和吉西他滨联合顺铂治疗晚期非小细胞肺癌疗效好，近期疗效相近，不良反应可耐受，初治较复治疗效好。Abstract: Objective To evaluate the clinical efficacy and side effects of Docetaxel/Cisplatin regimen and Gecitabine/Cisplatin regimen in the patients with advanced non-small-cell lung cancer(NSCLC). Methods Seventy-six patients with advanced NSCLC who were chemotherapy-naive were enrolled in two groups randomly.In docetaxel group(DP group) the patients received Docetaxel 75mg/m2 and Cisplatin 60mg/m2 on day 1.In Gemcitabine group(GP group) the patients received Gemcitabine 1000 mg/m2 on day 1 and day 8.The dosage of Cisplatin was the same as DP group.The two regimens were administrated intravenously every 21 days as a cycle，each patient received 2～4 cycles.All patients were followed up until disease progressed or patients died. Results The overall response rates were 43.5% in DP group and 45.9% in GP group. The response rate was significant difference between the initial treated group and retreated group(53.8% vs. 23.0% in DP group and 56% vs. 25% in GP group，P<0.05，respectively).The main toxicity was myelosuppression and decreasing platelet. Conclusion Docetaxel/Cisplatin regimen and Gecitabine/Cisplatin regimen of the patients with advanced NSCLC are efficient and well-tolerated chemotherapeutic approaches with low toxicity levels.The efficacy and major toxicity in two groups are similar.The effect of the initial group is better than that of the retreated group.
下载:
